Search
Kymera Therapeutics Inc
KYMRAdd to Watchlist
103.400USD
-3.610-3.37%
Close 07-31 16:00（ET）Quotes delayed by 15 min
8.51BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Kymera Therapeutics Inc is 8.52, ranking 107 out of 385 in the Biotechnology & Medical Research industry. The average price target is 90.50, with a high of 138.00 and a low of 65.00.
Analyst Rating
Based on
24
analysts
Buy
Current Rating
127.524
Target Price
+21.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Kymera Therapeutics Inc
KYMR
24
Beigene Ltd
ONC
28
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Kymera Therapeutics Inc's expected revenue for the next quarter?
Kymera Therapeutics Inc's expected revenue is 31.16M.
What is Kymera Therapeutics Inc's price target?
Analysts forecast that Kymera Therapeutics Inc's price target is USD 90.50, with the highest forecast at USD 138.00 and the lowest forecast at USD 65.00.
How have Kymera Therapeutics IncKYMR's recent earnings per share performed?
The market expectation was USD -0.71, while Kymera Therapeutics IncKYMR's earnings per share (EPS) for the previous quarter was USD -0.97. EPS for the next quarter is expected at USD -0.71.
What is the analyst rating for Kymera Therapeutics Inc?
Based on the ratings of Kymera Therapeutics Inc's stock from 24 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.